BridgeMD
Self-Assessment Method for Statin side-effects Or Nocebo 2
EU CTIS ID: 2025-524955-30-01
What this study is testing
To compare the proportion of patients who continue with intended dose of 20 mg rosuvastatin treatment six months after participating in a 36-week N-of-1 trial versus standard of care (statin titration) in patients with previously reported statin intolerance.
- Phase III and phase IV (Integrated)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- • Aged 18 years or older • Previously taken two or more statins • Withdrawn from statin treatment because of perceived side effects • Clinical indication for statins for primary or secondary prevention of cardiovascular disease
You likely can't join if
- • History of any condition that causes chronic pain • History of severe mental illness • Currently use of fibrates • History of statin intolerance with anaphylaxis • History of creatin kinase elevation >5 times upper limit of normal • History of statin intolerance with liver function abnormalities, defined as aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >3 times the upper limit of normal • Pregnant, breastfeeding, or planning to become pregnant during the study period. • Current use of red yeast rice • Per discretion of study doctor, if participant should not be enrolled on the study • Lack of access to a smartphone with an internet connection
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.